A double blind, randomized, placebo-controlled trial

Project: Research project

Project Details

Description

A double blind, randomized, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with "Systemic Sclerosis associated Interstitial Lind Disease (SSc-ILD)
StatusFinished
Effective start/end date12/14/156/30/19

Funding

  • Boehringer-Ingelheim Pharmaceuticals

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.